Our board is made up of prominent members of the scientific and business community. As current and previous directors in the areas of biotechnology, pharmaceuticals and scientific portfolio management, they bring valued experience to NuChem Therapeutics.

  • Dr. Holzbaur is the co-founder and co-manager of the AmorChem L.P. fund. She started her venture capital career at GeneChem Technologies L.P., which she joined in 1999. In 2002, she became a vice-president of GeneChem Therapeutics L.P. and finally General Partner of AgeChem L.P. in 2006.

    She has held several positions as board member of GeneChem portfolio companies in Canada, the US and Europe. Most notably, she was a member of the board of BioVex inc. and Argos Therapeutics inc. She obtained her PhD in chemistry, studying the stereospecificity of the biosynthesis of erythromycin at Cambridge University and before joining GeneChem, was a consultant in the Department of Food Science of McGill University. Her work has been published in Chemistry and Biology, the Journal of the American Chemical Society, Biochemistry and a review of infra-red spectroscopy.

    Show more
  • Mr. LeBel is currently President of Nuchem Therapeutics. He co-founded Anapharm, a phase I CRO, where he served as President and CEO. Anapharm grew from 8 employees to 1200 employees in Quebec City, Montréal, Trois-Rivières, Toronto and Barcelona. In addition he served as Executive Vice-President of Pharmanet, from 2005 to 2007, following the acquisition of Anapharm. He was also interim CEO of Warnex Inc., 2012-2013 where he led the process that led to the sale of Warnex Bioanalytical to Biotrials. He was also an active member of the following Boards of Directors: Université Laval, Acasti Inc. and Asmacure.

    As a movie and TV producer, Marc participated in The Legend of Sarila (2013), Snowtime (2015) (short-listed for the feature film award in animation at the Oscars), and Anna (2015).

    He is the author of 120 publications and more than 130 communications. Mr. LeBel received the Excelsia 2006 from BioQuébec, the leadership prize from the Canadian Society of Pharmaceutical Sciences and the Prix des Grands Diplômés from Université Laval.

    Show more
  • Dr. Gillard is President of the biotechnology consulting firm, BioGill Consultants Inc. He brings a wealth of experience in drug discovery and development, to the Board of NuChem Therapeutics. An accomplished organic chemist with past experience as Director of Medicinal Chemistry at Merck Research Laboratories; VP Research at Canada’s most successful biotech company, BioChem Pharma, and most recently as founder, CSO and EVP of Aegera Therapeutics Inc. Dr. Gillard directly participated in more than ten clinical development programs, several of which have become major, multi-billion drugs (Singulair(R) Epivir(R) and Lamivudine(R)).

    Dr. Gillard held executive management positions, Scientific Advisory Board memberships and Board Directorships of a number of private and public biotechnology companies across Canada. These companies include Stressgen, GlycoDesign and Apoptogen Kinetek and IBEX Technologies. Dr. Gillard has non-profit Board experience as a Director of the Ottawa Life Sciences Council, helping to promote biotech industry in Eastern Ontario.

    Dr. Gillard maintains strong academic ties and involvement, he has an extensive publication record and is currently Adj. Professor in the Department of Pharmacology and Therapeutics at McGill University, where he teaches and mentors graduate students. He is also very active in the Canadian University/Granting Council and funding programs field.

    Show more
  • Mr. Lacasse joined GeneChem at its inception in 1997. Prior to that, he was Vice-President of Healthcare and Biotechnology at Sofinov, a wholly owned venture capital subsidiary of Caisse de dépôt et placement du Québec. In total, he spent ten years with the Caisse where he was responsible for numerous investments in small and medium sized businesses in cutting-edge industries such as biotechnology, software and telecommunications. Mr. Lacasse has been involved in a number of very successful investments in companies such as BioChem Pharma inc., Axcan Pharma inc., and Neurocrine Biosciences inc.

    Mr. Lacasse is or has been a member of the board of directors of several companies including BioChem Pharma inc., Axcan Pharma inc. and Metrowerks inc. He has held positions with the Bank of Montreal and with the "Centre de développement technologique" of École Polytechnique de Montréal. Mr. Lacasse obtained a Bachelor's degree in finance from the École des Hautes Études Commerciales ("HEC") and a M.B.A. from McGill University. In 2008, he became a member of the Institute of Corporate Directors.

    Show more